Form 4: Allarity Therapeutics CFO Alexander Epshinsky Reports Acquisition of 29,496 Shares

CFO of Allarity Therapeutics, Alexander Epshinsky, reports acquiring 29,496 shares of common stock on January 22, 2025.

Summary

• Alexander Epshinsky, CFO of Allarity Therapeutics, filed a Form 4 on January 24, 2025.
• The report details a transaction on January 22, 2025, where Mr. Epshinsky acquired 29,496 shares of Allarity Therapeutics common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Mr. Epshinsky beneficially owns 85,051 shares of common stock.
• The acquisition also involved restricted stock units (RSUs) granted under the company's Amended and Restated 2021 Equity Incentive Plan.
• These RSUs will vest in equal one-third installments on the first, second, and third anniversary of the grant date, contingent upon continued service with the Issuer.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The CFO increasing his stake is mildly positive, but it's not a major event.

Positives

• The acquisition of shares by the CFO could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs (one-third annually over three years) suggests a long-term commitment from the CFO to the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CFO's increased stake in the company, aligning his interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the CFO's increased stake as a positive sign of confidence in the company's future.

Key Dates

Keywords

Allarity Therapeutics, Alexander Epshinsky, CFO, Form 4, Beneficial Ownership, Stock Acquisition, RSUs, ALLR